Original articlesBreast cancerReduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
Breast cancer
Under an Elsevier user license
open archive
Keywords
cardiotoxicity
pegylated liposomal doxorubicin
Cited by (0)
- †
M. E. R. O’Brien and N. Wigler contributed equally to this work
Copyright © 2004 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.